OncoMatch/Clinical Trials/NCT06232083
A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR)
Is NCT06232083 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies non-drug interventions for lung cancer.
At present, the treatment methods for recurrent cancers are very limited. The immune checkpoint inhibitors (ICBs) is a promising new directions for recurrent lung cancer/ esophageal cancer / cervical cancer, but the clinical response rate is insufficient. Pulse low-dose rate radiotherapy (PLDR) is a new technology in recent years, which uses continuous pulse low-dose rate irradiation to induce hypersensitivity in tumors, and its clinical safety has been verified. Compared to conventional radiotherapy, PLDR has advantages in protecting the lymphatic system and relieving the immune barrier, but it is still unclear whether it can improve the efficacy of ICB. This project aims to combine PLDR with ICB to explore new strategies for recurrent patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Esophageal Carcinoma
Cervical Cancer
Disease stage
Metastatic disease required
Recurrent or metastatic patients with previous treatment progress; According to RECIST 1.1 standard, there was at least one extracranial measurable lesion
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-tumor treatment
Recurrent or metastatic patients with previous treatment progress
Cannot have received: other anti-tumor treatment (concurrent)
Receiving any other anti-tumor treatment at the same time
Cannot have received: investigational drug
Patients who had participated in clinical trials of other drugs within 4 weeks before enrollment
Cannot have received: radiotherapy
who had received radiotherapy for the target area within 4 weeks before entering this study
Lab requirements
Blood counts
HGB≥90g/L; WBC ≥ 4.0 × 10^9/L; Neut ≥ 2.0 × 10^9/l; PLT ≥ 100 × 10^9/l
Kidney function
Bun and Cr ≤ 1.5 × ULN and creatinine clearance rate ≥ 50 ml/min
Liver function
TBIL ≤ 1.5 × ULN; ALT and AST ≤ 3 × ULN (ALT and AST ≤ 5 × ULN in patients with liver metastasis)
Cardiac function
LVEF >50% by echocardiography; exclusion for NYHA III-IV heart failure, severe arrhythmias, QTCF >470 ms, recent MI/angina/ischemia/thrombosis
The laboratory test results within one week before enrollment meet the following conditions: 1) blood routine: HGB≥90g/L； WBC ≥ 4.0 × 109/L; Neut ≥ 2.0 × 109/l; PLT ≥ 100 × 109/l; 2) Blood biochemistry: TBIL ≤ 1.5 × ULN; ALT and AST ≤ 3 × ULN (ALT and AST ≤ 5 × ULN in patients with liver metastasis); Bun and Cr ≤ 1.5 × ULN and creatinine clearance rate ≥ 50 ml/min; 3) The results of echocardiography within two weeks before admission were consistent: left ventricular ejection fraction (LVEF)>50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify